Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05862649 · ClinicalTrials.gov registry record · NA
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
A NA study of Parkinson Disease, sponsored by NeuraLight.
- Recruiting
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 5
- Study locations
NCT05862649: Recruiting NA study of Parkinson Disease, sponsored by NeuraLight.
NCT05862649 is a NA study of Parkinson Disease that is actively recruiting participants, run by NeuraLight. The registered enrollment target is 300 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05862649, a NA study of Parkinson Disease, is actively recruiting participants, sponsored by NeuraLight.
- RECRUITING
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multicenter longitudinal study in about 300 patients with Idiopathic Parkinson's disease, who will be evaluated in several clinical centers with a clinical assessment and an oculometric examination during a time period with specific intervals. This study aims to evaluate the correlation between oculometric measures and clinical assessment over time, as well as the potential to detect early change in clinical status using an oculometric assessment.
Primary Outcome
Difference between saccadic latency (ms) as quantified during each visit by the NeuraLight test measured using a statistical comparison of values (e.g. t-test, ANOVA), p\>0.05) over time during study period
Conditions Studied
Interventions
- OTHER NeuraLight
Study Locations (5)
Other
- AIBILI research center - Coimbra
- Instituto de Biomedicina de Sevilla (IBiS) - Seville
- University Hospital Zürich - Zurich
- The VCTC - Oxford
Illinois
- Rush University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-08-21 |
| Est. Completion | 2025-11-15 |
| Phase | NA |
What NCT05862649 shows while recruiting
NCT05862649 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which NeuraLight is the first listed.
NCT05862649 lists 5 locations in 2 states (Other, Illinois).
Frequently Asked Questions
What is clinical trial NCT05862649 about?
NCT05862649 is a clinical study titled "Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease". This is a multicenter longitudinal study in about 300 patients with Idiopathic Parkinson's disease, who will be evaluated in several clinical centers with a clinical assessment and an oculometric examination during a time period with specific intervals. This study aims to evaluate the correlation be...
What is the current status of trial NCT05862649?
This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2023-08-21. Estimated completion is 2025-11-15.
What conditions does trial NCT05862649 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT05862649?
The interventions under investigation include: NeuraLight (OTHER).
Who is sponsoring clinical trial NCT05862649?
This trial is sponsored by NeuraLight, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05862649 being conducted?
This trial has 5 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05862649's enrollment target sits among peer trials
300 36th of 297 higher than 262 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Neurophysiology of Reward Signaling in Parkinson's Disease
RECRUITING · NA
-
Balance Tele-Rehab in Parkinson's Disease Parkinson's Disease
RECRUITING · NA
-
Rock Steady Boxing: A Community Based In Person Class
RECRUITING · NA
-
Corticostriatal Contributions to Parkinson's Disease Cognitive Impairment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI